Carmustine
Carmustine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Autologous Stem Cell Transplant、Classic Hodgkin Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
20 项
全球在招研究
4 项
已进入 III/IV 期
4 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Masonic Cancer Center, University of Minnesota
- Thomas Jefferson University
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Chinese PLA General Hospital
- The First Affiliated Hospital with Nanjing Medical University
- VIVUS LLC
- City of Hope Medical Center
- Leland Metheny
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、瑞士、Russia
正在招募患者的 Carmustine 研究
Tebentafusp-tebn With LDT in Metastatic UM
I 期 / II 期招募中美国NCT06626516Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
I 期招募中美国NCT05083754Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
IV 期招募中中国NCT07101588A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
III 期招募中中国NCT05931263Auto Stem Cell Transplant for Lymphoma Patients
II 期招募中美国NCT03125642A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
II 期招募中美国NCT06915246Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
II 期招募中美国NCT04871607hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
II 期招募中美国NCT05052957Early Pulmonary Dysfunction in Childhood Cancer Patients
不适用招募中瑞士NCT05427136Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
II 期招募中中国NCT05088226CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
II 期招募中美国NCT06687772MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
II 期招募中美国NCT06377540Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
I 期招募中美国NCT05432635A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
II 期招募中美国NCT04222062Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
II 期招募中中国NCT07199296SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
I 期招募中美国NCT04150042B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
IV 期招募中RussiaNCT05518383Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
I 期招募中美国NCT05521984Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
III 期招募中美国NCT04047628CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
II 期招募中中国NCT07538635
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。